Allergy Therapeutics PLC

AGY.L

$0.06

Closing

0.00

1D

▲70.00%

YTD

AGY

BBG001SGQRM9

Market cap

$264.68M

52 week high

$0.08

52 week low

$0.02

Volume

40,815

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $6.99/month

Market cap

$264.68M

Analysts' Rating

-

Price Target (Mean)

0.17

Total Analysts

0

P/E

Operating Margin

-35.40%

Beta

1.92

Revenue Growth

-15.86%

52 week high

$0.08

52 week low

$0.02

Div. Yield

%

EPS Growth

0.00

Company Profile

Allergy Therapeutics plc is a United Kingdom-based integrated specialty pharmaceutical company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum-free immunotherapy vaccines that have the potential to cure disease. The Company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional ten countries. Its pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA, Bee Venom SCIT, Wasp Venom SCIT, Ragweed MATA MPL, Trees MATA, Trees MATA MPL, Peanut SCIT and others. Its commercial portfolio of products includes Pollinex, Venomil and Acarovac. It operates in Austria, Germany, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom.